Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: Results of a prospective study in 140 patients

Clinical Cancer Research

Volumn 20, Issue 11, 2014, Pages 2984-2993

  Mayerhoefer, Marius E ^a   Karanikas, Georgios ^a   Kletter, Kurt ^a   Prosch, Helmut ^a   Kiesewetter, Barbara ^a   Skrabs, Cathrin ^a   Porpaczy, Edit ^a   Weber, Michael ^a   Pinker Domenig, Katja ^a   Berzaczy, Dominik ^a   Hoffmann, Martha ^a   Sillaber, Christian ^a   Jaeger, Ulrich ^a   Müllauer, Leonhard ^a   Simonitsch Klupp, Ingrid ^a   Dolak, Werner ^a   Gaiger, Alexander ^a   Ubl, Philipp ^a   Lukas, Julius ^a   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOMEPROL; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; FEMALE; FOLLICULAR LYMPHOMA; GOLD STANDARD; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; WHOLE BODY MRI; ADOLESCENT; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC USE; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOMA; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84901781519     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3355     Document Type: Article

References (32)

1. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51:25-30.
2. Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, et al. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol 2010;194:W91-103.
3. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-54.
4. Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013;24:561-76.
5. Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 2013;24:2108-12.
6. Wöhrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG- PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780 -4.
7. Hoffmann M,Wöhrer S, Becherer A, Chott A, Streubel B, Kletter K, et al. 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol 2006;17:1761-5. (Pubitemid 44884049)
8. Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG- PET with 67gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110:652-9. (Pubitemid 47106156)
9. Perry C, Herishanu Y, Metzer U, Bairey O, Ruchlemer R, Trejo L, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 2007;79:205-9. (Pubitemid 47231161)
10. Radan L, Fischer D, Bar-Shalom R, Dann EJ, Epelbaum R, Haim N, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging 2008;35:1424-30.
11. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013;24:857-77.
12. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008;111:504-16.
13. Kim S, Loevner L, Quon H, Sherman E, Weinstein G, Kilger A, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009;15: 986- 94.
14. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognosticassessment by diffusionweighted MRI. Clin Cancer Res 2012;18:1146-55.
15. Fujimoto H, Kazama T, Nagashima T, Sakakibara M, Suzuki TH, Okubo Y, et al. Diffusion-weighted imaging reflects pathological therapeutic response and relapse in breast cancer. Breast Cancer 2013 Feb 12. [Epub ahead of print].
16. Wang HJ, Pui MH, Guo Y, Yang D, Pan BT, Zhou XH. Diffusionweighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection. Abdom Imaging 2014;39:135-41.
17. Nural MS, Danaci M, Soyucok A, Okumus NO. Efficiency of apparent diffusion coef ficients in differentiation of colorectal tumor recurrences and posttherapeutical soft-tissue changes. Eur J Radiol 2013;82: 1702- 9.
18. Lin C, Luciani A, Itti E, El-Gnaoui T, Vignaud A, Beaussart P, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010;20:2027-38.
19. van Ufford HM, Kwee TC, Beek FJ, van Leeuwen MS, Takahara T, Fijnheer R, et al. Newly diagnosed lymphoma: initial results with wholebody T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG-PET/CT. AJR Am J Roentgenol 2011;196:662-9.
20. Abdulqadhr G, Molin D, Aström G, Suurküla M, Johansson L, Hagberg H, et al. Whole-body diffusion-weighted imaging compared with FDGPET/ CT in staging of lymphoma patients. Acta Radiol 2011;52:173-80.
21. Stéphane V, Samuel B, Vincent D, Joelle G, Remy P, Francois GG, et al. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol 2013;82:2011-7.
22. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368-76. (Pubitemid 41677378)
23. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254:47-66.
24. Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B. Diffusionweighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging 2011;33:128 -35.
25. Kiliçkesmez O, Yirik G, Bayramgǒlu S, Cimilli T, Aydin S. Non-breathhold high b-value diffusion-weighted MRI with parallel imaging technique: apparent diffusion coefficient determination in normal abdominal organs. Diagn Interv Radiol 2008;14:83-7. (Pubitemid 352002996)
26. Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011;197: W384 -91.
27. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643-51. (Pubitemid 46224066)
28. Choi D, Lim HK, Lee SJ, Lim JH, Kim SH, Lee WJ, et al. Gastric mucosa-associated lymphoid tissue lymphoma: helical CT findings and pathologic correlation. AJR Am J Roentgenol 2002;178: 1117 - 22.
29. Kwee TC, Vermoolen MA, Akkerman EA, Kersten MJ, Fijnheer R, Ludwig I, et al. Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: Comparison with CT in a prospective multicenter study. J Magn Reson Imaging 2013 Oct 31. [Epub ahead of print].
30. El-Galaly TC, d'Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomogra-phy- staged treatment-naïve patients with Hodgkin lymphoma. J Clin Oncol 2012;30:4508-14.
31. Raderer M, Streubel B, Woehrer S, Puespoek A, Jaeger U, Formanek M, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005;11:3349-52. (Pubitemid 40627886)
32. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, et al. EGILS group. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60: 747- 58.